Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -225.28% is 56% above its 5-year average of -512.02%, near the high end of its 5-year range (-2798.86%–-165.34%).
13.16% above its 12-month average of -259.43%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -165.34%.
NET PROFIT MARGIN
-225.28%
NET PROFIT MARGIN AVG TTM
-259.43%
NET PROFIT MARGIN AVG 3Y
-435.83%
NET PROFIT MARGIN AVG 5Y
-512.02%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+13.16%
CURRENT VS 3Y AVG
+48.31%
CURRENT VS 5Y AVG
+56.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.02%
median of 851 covered companies
CURRENT VS SECTOR MEDIAN
-1126300.00%
vs the sector median at left
Lucyd, Inc
Market Cap
$5.85M
Net Profit Margin
-225.28%
TTM Avg
-259.43%
3Y Avg
-435.83%
5Y Avg
-512.02%
Market Cap
$5.83M
Net Profit Margin
-4620.92%
TTM Avg
-1491.69%
3Y Avg
-1081.40%
5Y Avg
-732.36%
Market Cap
$5.87M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-86.55%
Market Cap
$5.94M
Net Profit Margin
-10.33%
TTM Avg
-20.23%
3Y Avg
-29.31%
5Y Avg
-29.79%
Market Cap
$5.75M
Net Profit Margin
-9366.75%
TTM Avg
-6298.14%
3Y Avg
-3910.26%
5Y Avg
-3305.87%
Market Cap
$5.98M
Net Profit Margin
-44771.83%
TTM Avg
-33930.36%
3Y Avg
-151894.64%
5Y Avg
-112740.11%
Market Cap
$5.63M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.56M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.22M
Net Profit Margin
-534.27%
TTM Avg
-983.65%
3Y Avg
-1060.24%
5Y Avg
-924.37%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucyd, Inc (LUCY) | $5.85M | -225.28% | -259.43% | -435.83% | -512.02% |
| Scienture Holdings, Inc. (SCNX)vs › | $5.83M | -4620.92% | -1491.69% | -1081.40% | -732.36% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.87M | 0.00% | 0.00% | 0.00% | -86.55% |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.94M | -10.33% | -20.23% | -29.31% | -29.79% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.75M | -9366.75% | -6298.14% | -3910.26% | -3305.87% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | -44771.83% | -33930.36% | -151894.64% | -112740.11% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | 0.00% | 0.00% | 0.00% | 0.00% |
| enVVeno Medical Corporation (NVNO)vs › | $5.56M | 0.00% | 0.00% | 0.00% | 0.00% |
| Femasys Inc. (FEMY)vs › | $6.22M | -534.27% | -983.65% | -1060.24% | -924.37% |
| Biomerica, Inc. (BMRA)vs › | $6.32M | -84.79% | -89.20% | -105.63% | -91.66% |
Operating Margin
-319.2%
Net Profit Margin
-225.3%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -165.34% |
| 2026-03-31 | -298.54% |
| 2025-12-31 | -194.84% |
| 2025-09-30 | -274.84% |
| 2025-06-30 | -363.60% |
| 2025-03-31 | -391.35% |
| 2024-12-31 | -307.83% |
| 2024-09-30 | -678.50% |
| 2024-06-30 | -631.20% |
| 2024-03-31 | -514.07% |
| 2023-12-31 | -388.74% |
| 2023-09-30 | -699.09% |
| 2023-06-30 | -757.85% |
| 2023-03-31 | -987.30% |
| 2022-12-31 | -2798.86% |
| 2022-09-30 | -924.16% |
| 2022-06-30 | -583.08% |
| 2022-03-31 | -511.21% |
| 2021-12-31 | -502.90% |
| 2021-09-30 | -643.61% |
| 2021-06-30 | -422.43% |
| 2021-03-31 | -189.30% |
| 2020-12-31 | -906.08% |
| 2020-09-30 | -1089.86% |
| 2020-06-30 | -2148.63% |
| 2020-03-31 | -2148.65% |
